Moreover, gefitinib treatment in high-fat diet Mig-6d/d mice showed decreases in fasting insulin concentration and insulin resistance, suggesting gefitinib may improve metabolic syndrome in those with dysregulated EGFR and/or its signaling pathway. The gene discussed is EGFR; the disease is Insulin resistance.